Changes in Registrant’s Certifying Accountant. New Independent Registered Public Accounting Firm As previously disclosed on a Current Report on Form 8-K with the Securities and Exchange Commission that Benitec Biopharma Inc. (the “Company”) filed on September 24, 2026, the Company reported the approval of the engagement of Ernst & Young LLP (“EY”) as the Company’s independent registered public accounting firm for the fiscal year ending June 30, 2027. The engagement was subject to EY completin…

Changes in Registrant’s Certifying Accountant. Baker Tilly US, LLP (“Baker Tilly”), the Company’s independent registered public accounting firm, has served as the Company’s auditor since 2020. As a matter of good corporate governance, the Company completed a process to review the engagement of the Company’s independent registered public accounting firm to audit the Company’s future consolidated financial statements. As further outlined below, as a result of such process, the Company appointed…

Results of Operations and Financial Condition. On September 14, 2026, Benitec Biopharma Inc. (the “Company”) issued a press release announcing the Company’s financial results for the fiscal year ended June 30, 2026 and providing an operational update. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information included in this Current Report on Form 8-K (including Exhibit 99.1 hereto) that is furnished pursuant to this

Director — Megan Boston: Ms. Boston resigned from the Board but continues as CFO and Secretary.

Results of Operations and Financial Condition. On May 14, 2026, Benitec Biopharma Inc. (the “Company”) issued a press release announcing the Company’s financial results for the fiscal quarter ended March 31, 2026 and providing an operational update. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information included in this Current Report on Form 8-K (including Exhibit 99.1 hereto) that is furnished pursuant to this

Results of Operations and Financial Condition. On February 12, 2026, Benitec Biopharma Inc. (the “Company”) issued a press release announcing the Company’s financial results for the fiscal quarter ended December 31, 2025 and providing an operational update. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information included in this Current Report on Form 8-K (including Exhibit 99.1 hereto) that is furnished pursuant to this

Results of Operations and Financial Condition. On November 14, 2025, Benitec Biopharma Inc. (the “Company”) issued a press release announcing the Company’s financial results for the fiscal quarter ended September 30, 2025 and providing an operational update. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information included in this Current Report on Form 8-K (including Exhibit 99.1 hereto) that is furnished pursuant to this

Entry into a Material Definitive Agreement. Underwritten Offering On November 5, 2025, Benitec Biopharma Inc., a Delaware corporation (the “Company”), entered into an Underwriting Agreement (the “Underwriting Agreement”) with Leerink Partners LLC (“Leerink Partners”), TD Securities (USA) LLC (“TD Securities”) and Evercore Group L.L.C. (“Evercore ISI”), as representatives of the several underwriters named therein (the “Underwriters”), pursuant to which the Company agreed to issue and sell, in…

Other Events. On November 5, 2025, the Company issued a press release announcing that it had priced the Offerings. A copy of the press release is attached as Exhibit 99.1 to this Current Report and is incorporated herein by reference. Forward-Looking Statements This Current Report contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Company has tried to identif…

Director — Dr. Sharon Mates: Dr. Sharon Mates was appointed as a director of the Board.

Results of Operations and Financial Condition. On September 22, 2025, Benitec Biopharma Inc. (the “Company”) issued a press release announcing the Company’s financial results for its full year ended June 30, 2025 and providing an operational update. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information included in this Current Report on Form 8-K (including Exhibit 99.1 hereto) that is furnished pursuant to this

Non-Reliance on Previously Issued Financial Statements or a Related Audit Report or Completed Interim Review. In connection with the preparation of Benitec Biopharma Inc.’s (“Benitec,” or the “Company”) Annual Report on Form 10-K for the fiscal year ended June 30, 2025 (the “2025 Form 10-K”), the Company determined that in prior periods it had not appropriately recorded certain non-cash share-based compensation expenses . Accordingly, on September 10, 2025, the Audit Committee (the “Audit Com…

Results of Operations and Financial Condition. On May 14, 2025, Benitec Biopharma Inc. (the “Company”) issued a press release announcing the Company’s financial results for its fiscal quarter ended March 31, 2025. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information included in this Current Report on Form 8-K (including Exhibit 99.1 hereto) that is furnished pursuant to this

Entry into a Material Definitive Agreement. On March 26, 2025, Benitec Biopharma Inc., a Delaware corporation (the “Company”) entered into a Registration Rights Agreement (the “Registration Rights Agreement”) with Averill Master Fund, Ltd. and Averill Madison Master Fund, Ltd. (together, the “Purchasers”) in connection with the closing of the previously announced registered direct offering conducted by the Company pursuant to the Registration Statement on Form S-3 (File No. 333- 282957), as s…

Other Events. On March 25, 2025, the Company issued a press release announcing that it had priced the Offerings, and that in connection with the Direct Offering it has discussed with Suvretta Capital appointing David Friedman, managing director at Suvretta Capital, to the Company’s board of directors, subject to approval by the Company’s board of directors and review by its Nominating and Governance Committee. A copy of the press release is attached as Exhibit 99.1 to this Current Report and…

Entry into a Material Definitive Agreement. Underwritten Offering On March 25, 2025, Benitec Biopharma Inc., a Delaware corporation (the “Company”), entered into an Underwriting Agreement (the “Underwriting Agreement”) with Leerink Partners LLC (“Leerink Partners”) and TD Securities (USA) LLC (“TD Cowen”), as representatives of the several underwriters named therein (the “Underwriters”), pursuant to which the Company agreed to issue and sell, in an underwritten offering by the Company (the “U…

Results of Operations and Financial Condition. On February 14, 2025, Benitec Biopharma Inc. (the “Company”) issued a press release announcing the Company’s financial results for its fiscal quarter ended December 31, 2024 and an operational update. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information included in this Current Report on Form 8-K (including Exhibit 99.1 hereto) that is furnished pursuant to this

Chief Operating Officer — Sophie Mukadam: Sophie Mukadam was promoted to Chief Operating Officer and granted stock options.

Chief Operating Officer — Sophie Mukadam: Sophie Mukadam was promoted to Chief Operating Officer.

Material Modification to Rights of Security Holders. The information included in

Results of Operations and Financial Condition. On November 14, 2024, Benitec Biopharma Inc. (the “Company”) issued a press release announcing the Company’s financial results for its fiscal quarter ended September 30, 2024. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information included in this Current Report on Form 8-K (including Exhibit 99.1 hereto) that is furnished pursuant to this

The filing details bonus payments for executives, not a management change.

Entry into a Material Definitive Agreement. On October 11, 2024, Benitec Biopharma Inc. (the “Company”) entered into a Sales Agreement (the “Sales Agreement”) with Leerink Partners LLC (the “Agent”). Pursuant to the terms of the Sales Agreement, the Company may offer and sell shares of the Company’s common stock, par value $0.0001 (the “Shares”) having an aggregate offering amount of up to $75 million from time to time through the Agent. The Agent will use its commercially reasonable efforts,…

Results of Operations and Financial Condition. On September 26, 2024, Benitec Biopharma Inc. (the “Company”) issued a press release announcing the Company’s financial results for its full year ended June 30, 2024 and providing an operational update. A copy of this press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information included in this Current Report on Form 8-K (including Exhibit 99.1 hereto) that is furnished pursuant to this

The excerpt is incomplete and does not provide enough information to determine the specific nature of the event.